Healthcare of Ontario Pension Plan Trust Fund cut its stake in shares of Balchem Co. (NASDAQ:BCPC – Get Rating) by 74.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,700 shares of the basic materials company's stock after selling 31,800 shares during the period. Healthcare of Ontario Pension Plan Trust Fund's holdings in Balchem were worth $1,463,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of BCPC. Intelligent Financial Strategies bought a new stake in Balchem in the fourth quarter worth $25,000. UMB Bank N A MO purchased a new position in shares of Balchem during the 4th quarter worth about $56,000. Carolinas Wealth Consulting LLC grew its holdings in Balchem by 130.5% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 484 shares of the basic materials company's stock valued at $82,000 after purchasing an additional 274 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in Balchem by 43.1% in the fourth quarter. First Horizon Advisors Inc. now owns 558 shares of the basic materials company's stock worth $93,000 after purchasing an additional 168 shares during the last quarter. Finally, Destiny Wealth Partners LLC boosted its position in shares of Balchem by 58.4% during the first quarter. Destiny Wealth Partners LLC now owns 659 shares of the basic materials company's stock valued at $90,000 after buying an additional 243 shares during the period. 89.15% of the stock is owned by institutional investors.
Get
Balchem alerts:
Balchem Trading Up 3.1 %
Shares of NASDAQ BCPC opened at $134.35 on Thursday. Balchem Co. has a twelve month low of $110.15 and a twelve month high of $174.29. The firm has a market cap of $4.32 billion, a PE ratio of 40.22 and a beta of 0.59. The business has a fifty day simple moving average of $131.75 and a two-hundred day simple moving average of $129.99. The company has a quick ratio of 1.64, a current ratio of 2.62 and a debt-to-equity ratio of 0.50.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the company. StockNews.com lowered Balchem from a "buy" rating to a "hold" rating in a research note on Monday, August 1st. HC Wainwright boosted their target price on shares of Balchem from $152.00 to $164.00 and gave the company a "buy" rating in a research note on Monday, August 22nd.
Insider Buying and Selling
In other news, VP Gunsteren Job Leonard Van sold 3,601 shares of the business's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $125.62, for a total value of $452,357.62. Following the completion of the sale, the vice president now owns 1,430 shares in the company, valued at approximately $179,636.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is owned by insiders.
Balchem Profile
(Get Rating)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Featured Stories
- Get a free copy of the StockNews.com research report on Balchem (BCPC)
- 3 High Margin Chipmakers Bound to Recover
- 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
- REV Group Has A Deep Moat In The World Of EVs
- Is G-III Apparel Group, Ltd. A Value Trap?
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.
